NEW YORK (GenomeWeb News) –Agilent Technologies and Kreatech Diagnostics today announced a licensing and supply agreement for the Dutch molecular diagnostic firm's ULS technology and products, broadening an existing collaboration between the two companies.
ULS is a direct chemical labeling technology that features a two-step labeling procedure "that allows the use of a broad range of fluorescent labels and haptens," the partners said in a statement. Nucleic acids can be labeled regardless of their length or composition, they added, making the technology "ideally suited" for reproducible and robust labeling of all species of DNA and RNA molecules, they added.
Financial and other terms of the deal were not disclosed.
In 2007, the two companies inked a licensing agreement for use of Kreatech's labeling technology with formalin-fixed, paraffin-embedded DNA tissue-extraction methods from Agilent.
"The new agreement fits very well into Kreatech's commercial strategy to become a significant supplier of products for the US market,” said Kees Moonen, CEO of Kreatech, in a statement.